ReviewPathobiology : journal of immunopathology, molecular and cellular biology2020
The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.
Review in Pathobiology : journal of immunopathology, molecular and cellular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Mast cell leukemia with complex genomic alterations in an elderly patient with prior hematologic and solid malignancies: a case report.Annals of medicine and surgery (2012) · 2026Article
- Case Report: Experience of a rare case of primary acute mast cell leukemia with FGFR1 gene rearrangement.Frontiers in oncology · 2026Article
- Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinib.Blood neoplasia · 2025Article
- Article
- Case report: Experience of a rare case of primary acute mast cell leukemia.Leukemia research reports · 2025Article
- Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype,Haematologica · 2024Article
- Treatment refractory mast cell leukemia with dominant gastrointestinal manifestation and concomitant skin symptoms: A case report.World journal of clinical cases · 2024Article
- Review
- Mast Cell Leukemia: An Update with a Practical Review.Cancers · 2023Review
- Comprehensive mastocytosis data analysis from a single center.BMC cancer · 2023Article
- Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management.International journal of molecular sciences · 2022Article
- Acute Mast Cell Leukemia Preceded by Malignant Mediastinal Germ Cell Tumor: A Case Report and Literature Review.Cancer management and research · 2022Article
- Precision Medicine in Systemic Mastocytosis.Medicina (Kaunas, Lithuania) · 2021Review
- Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021Review
- Sometimes it is Not as Simple as Sepsis: An Unusual Cause of Coagulopathy.The American journal of medicine · 2021Article
- Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review.Frontiers in oncology · 2021Article
- Article
- Acute aleukemic mast cell leukemia: Report of a case and review of the literature.Leukemia research reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most cases of mastocytosis are indolent, usually cutaneous mastocytosis or indolent systemic mastocytosis (SM). Aggressive mast cell (MC) diseases are very rare and often fatal. They can develop de novo or due to progression of indolent forms and can present in different ways; either as MC sarcoma or as advanced SM which includes aggressive SM, MC leukemia, and SM with an associated hematological neoplasm. This review will describe these different aggressive forms of mastocytosis, illustrated by cases submitted to the workshop of the 18th Meeting of the European Association for Haematopathology, Basel 2016, organized by the European Bone Marrow Working Group. In addition, the diagnostic criteria for identifying myelomastocytic leukemia, an aggressive myeloid neoplasm with partial MC differentiation that falls short of the criteria for SM, and disease progression in patients with established mastocytosis are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.